$INKT Q2 '26 Earnings Results & Recap MiNK Therapeutics reported a net loss of $3.1 million, or $0.62 per share, for the second quarter of 2026, with cash and cash equivalents totaling $8.8 million as of June 30.
$INKT Q2 '26 Earnings Results & Recap MiNK Therapeutics reported a net loss of $3.1 million, or $0.62 per share, for the second quarter of 2026, with cash and cash equivalents totaling $8.8 million as of June 30.